Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419694 | 0.88 | CNR2 (0.54) | KDM4EL3MBTL1CES2CES1SNCA | |
| SCHEMBL6419870 | 0.88 | CES2 (0.49) | KDM4EL3MBTL1CES2CES1SNCA | |
| SCHEMBL15248904 | 0.85 | ESRRG (0.48) | KDM4EL3MBTL1NPSR1ANO1HDAC4 | |
| SCHEMBL6415999 | 0.84 | CES2 (0.45) | L3MBTL1CES2CES1SNCACNR1 | |
| SCHEMBL6419619 | 0.83 | POLB (0.56) | KDM4EL3MBTL1CES2CES1SNCA | |
| SCHEMBL7528084 | 0.83 | CES2 (0.41) | L3MBTL1NPSR1CES2CES1SNCA | |
| SCHEMBL7528950 | 0.82 | L3MBTL1 (0.42) | L3MBTL1NPSR1CES2CES1SNCA | |
| SCHEMBL7527282 | 0.81 | CES2 (0.42) | KDM4EL3MBTL1CES2CES1SNCA | |
| SCHEMBL10330517 | 0.81 | NPSR1 (0.58) | KDM4EL3MBTL1NPSR1NPC1RAB9A | |
| SCHEMBL6420439 | 0.81 | CES2 (0.52) | KDM4EL3MBTL1CES2CES1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | KDM4E 1808/4885L3MBTL1 3197/4885NPSR1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.